International Assets Investment Management LLC Buys Shares of 53,508 Arvinas, Inc. (NASDAQ:ARVN)

International Assets Investment Management LLC bought a new stake in Arvinas, Inc. (NASDAQ:ARVN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 53,508 shares of the company’s stock, valued at approximately $2,202,000. International Assets Investment Management LLC owned 0.10% of Arvinas as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of ARVN. Norges Bank bought a new position in Arvinas in the fourth quarter valued at about $24,007,000. FMR LLC lifted its holdings in Arvinas by 10.6% in the third quarter. FMR LLC now owns 4,868,295 shares of the company’s stock valued at $95,613,000 after acquiring an additional 466,667 shares during the period. BlackRock Inc. lifted its holdings in Arvinas by 9.6% in the second quarter. BlackRock Inc. now owns 4,903,469 shares of the company’s stock valued at $121,704,000 after acquiring an additional 427,871 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Arvinas by 8.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,368,130 shares of the company’s stock valued at $81,014,000 after acquiring an additional 188,362 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in Arvinas in the first quarter valued at about $4,790,000. Institutional investors own 95.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ARVN shares. HC Wainwright decreased their price objective on Arvinas from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Wedbush raised their price objective on Arvinas from $33.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Arvinas in a research note on Thursday, February 22nd. Truist Financial reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Arvinas in a research note on Monday, March 25th. Finally, Barclays raised their price objective on Arvinas from $26.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $59.73.

Arvinas Price Performance

NASDAQ:ARVN opened at $34.72 on Friday. Arvinas, Inc. has a 1 year low of $13.57 and a 1 year high of $53.08. The stock’s 50 day simple moving average is $43.27 and its two-hundred day simple moving average is $34.05. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -5.34 and a beta of 1.94.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). Arvinas had a negative return on equity of 70.24% and a negative net margin of 185.09%. The firm had revenue of ($43.10) million during the quarter, compared to the consensus estimate of $38.91 million. During the same period in the previous year, the firm earned ($1.56) EPS. As a group, analysts anticipate that Arvinas, Inc. will post -5.02 EPS for the current year.

Insiders Place Their Bets

In other Arvinas news, CEO John G. Houston sold 5,196 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $244,471.80. Following the sale, the chief executive officer now owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Arvinas news, CEO John G. Houston sold 5,196 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $244,471.80. Following the sale, the chief executive officer now owns 1,036,681 shares of the company’s stock, valued at approximately $48,775,841.05. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ronald Peck sold 1,699 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the transaction, the insider now directly owns 67,516 shares in the company, valued at approximately $3,176,627.80. The disclosure for this sale can be found here. Insiders have sold a total of 8,597 shares of company stock valued at $404,489 in the last quarter. 2.55% of the stock is currently owned by insiders.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.